|
|
Article: Development program initiated for combined MC-1 and angiotensin receptor blocker.
- Article from:
- Hematology Week
- Article date:
- December 20, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 DEC 20 - (NewsRx.com & NewsRx.net) -- Medicure Inc. (TSX:MPH; Amex: MCU) announced the initiation of the development program for a drug combining MC-1 and an angiotensin receptor blocker (ARB), one of the world's ten largest pharmaceutical drug classes by revenue.
The patented new product, MC-4262, is being developed for use in the treatment of hypertension in patients whose condition is complicated with metabolic syndrome resulting in increased cardiovascular risk.
Metabolic syndrome is a cluster of disorders that include obesity, high blood pressure, elevated blood sugar and hyperlipidemia. The American Heart Association estimates that ...